BioSpace News Archive

Business

Busy Healthcare Executive Pens Bestselling Diet Book Z-FAST: A Simple Proven Method of Intermittent Fasting

Author John Zehren Has Discovered The Secret to Losing Weight and Keeping It Off

June 11, 2018
·
2 min read
Beleave Inc. Announces Closing of First Tranche of Non-Brokered Private Placement of Units

The Company may, at its discretion, increase the size of the Non-Brokered Offering.

June 11, 2018
·
3 min read
BioMidwest

The Future Looks Brighter Thanks to Prospective Sustainability Innovations for Procter & Gamble’s Tide®

Procter & Gamble (P&G) announced presentations given on new research into sustainability innovations for its Tide® laundry detergent.

June 11, 2018
·
4 min read
Drug Development

NeuroRx, Inc. Completes Phase 2b/3 Feasibility Enrollment for First Glx-Targeted Oral Drug Targeting Suicidal Bipolar Depression

NRX-101 was awarded FAST TRACK designation by the FDA in August 2017 as an experimental agent for the treatment of Severed Bipolar Depression with Acute Suicidal Ideation or Behavior.

June 11, 2018
·
7 min read
Business

Matt Pammer appointed as Prime Therapeutics’ Chief Information Officer

Prime Therapeutics LLC has named Matt Pammer chief information officer (CIO) and senior vice president.

June 11, 2018
·
2 min read
Sinovac Biotech Relaunches Company Website

Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), today announced that the company has relaunched its website, at www.sinovacbio.com.

June 11, 2018
·
2 min read
Genetown

Can Your DNA Predict Opioid Addiction? New Research Partnership Between Bentley University and Gravity Diagnostics Will Explore the Genetic Link to Opioid Abuse

Bentley University and Gravity Diagnostics have announced a partnership to conduct research that could inform doctors prescribing pain medication how likely a patient is to become addicted and predict how those already addicted to opioids will respond to certain treatments.

June 11, 2018
·
4 min read
Drug Development

FDA Approves Addition Of Positive Overall Survival Data From Phase 3 ASPIRE Trial To KYPROLIS® (carfilzomib) Label

KYPROLIS, Lenalidomide and Dexamethasone Extended Median Overall Survival in Relapsed or Refractory Multiple Myeloma Patients to 48 Months KYPROLIS is the First and Only Treatment to Demonstrate Overall Survival Benefits in Two Phase 3 Studies in Relapsed or Refractory Multiple Myeloma

June 11, 2018
·
19 min read
BioForest

D-1 Before First Ever International NASH Day: Detailed Program Announcement & Liver Forum Endorsement

A first-of-its-kind disease awareness event, the First International NASH Day

June 11, 2018
·
12 min read
Business

Pamela Guoth, M.D. Has Recently Been Recognized as a Strathmore’s Who’s Who Professional of the Year

Pamela Guoth, M.D., of Panama City Beach, Florida, has recently been honored as a 2018 Professional of the Year by Strathmore’s Who’s Who for her outstanding contributions and achievements in field of Emergency Medicine.

June 11, 2018
·
1 min read